- Home
- HFRO vs MNPR Comparison
HFRO vs MNPR Comparison
Compare HFRO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFRO | MNPR |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 403.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HFRO | MNPR |
|---|---|---|
| Price | $5.78 | $62.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | 90.3K | ★ 149.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.24 | $26.06 |
| 52 Week High | $6.83 | $105.00 |
Technical Indicators
Market Signals| Indicator | HFRO | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 32.96 | 60.14 |
| Support Level | $5.03 | $50.92 |
| Resistance Level | $6.24 | $89.51 |
| Average True Range (ATR) | 0.13 | 3.16 |
| MACD | -0.03 | 1.20 |
| Stochastic Oscillator | 11.67 | 83.13 |
Price Performance
Historical ComparisonAbout HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.